Join our daily newsletter At The Bell to receive exclusive market insights
- Zelira Therapeutics (ZLD) completes enrolment of two-thirds of patients for its diabetic nerve pain drug trial
- The company has now enrolled 40 out of 60 patients in the clinical trial, in which Zelira will go head-to-head against a major pharmaceutical company’s multi-billion-dollar revenue drug using its proprietary product
- A complete enrolment and trial read out is scheduled for the fourth quarter of this financial year
- Zelira Therapeutics is down 1.36 per cent to trade at $1.45 at 12:35 pm AEST
Zelira Therapeutics (ZLD) has completed the enrolment of two-thirds of patients for its diabetic nerve pain drug trial.
The company has now enrolled 40 out of 60 patients in the clinical trial, which will go head-to-head against a major pharmaceutical company’s multi-billion-dollar revenue drug, using Zelira’s proprietary product.
Zelira Therapeutics CEO and Managing Director Dr Oludare Odumosu said the company is pleased with its pace of enrolment and is now focused on completing the full patient recruitment for this trial.
Earlier this year, Zelira announced the complete enrolment of 20 patients in arm one, which was the investigative drug arm of the trial.
An additional 20 subjects currently using the Big Pharmaceutical company drug have now been successfully enrolled. The second arm will serve as an active reference arm for the trial. This will be followed by a third arm to evaluate the combined effects of the reference drug.
“Zelira’s product has the potential to be comparable to the Big Pharmaceutical reference product or show significant difference in measures of increased efficacy, safety and tolerability,” Dr Oludare Odumosu said.
“Delivering on one or more of these endpoints would be a significant milestone for our company and further validate Zelira’s ability to create meaningful cannabinoid-based drugs that are safe and efficacious in treating various conditions.”
A complete enrolment and trial read out is now scheduled for the fourth quarter of this financial year.
Zelira Therapeutics was down 1.36 per cent to trade at $1.45 at 12:35 pm AEST.
